Update on the management of Lennox-Gastaut syndrome with a focus on rufinamide

Research output: Contribution to journalArticle

Abstract

Objective: This review summarizes the treatment of Lennox-Gastaut syndrome, an intractable epileptic encephalopathy of early childhood. In particular, the review focuses on rufinamide, a recently released anticonvulsant medication with reported effectiveness in this epilepsy syndrome. Methods: A systematic literature search (PubMed) was performed to review the existing literature pertaining to the treatment of Lennox-Gastaut syndrome as well as studies involving rufinamide as an anticonvulsant medication. Results: The published literature to date documents a beneficial effect of rufinamide on children over 4 years old with Lennox-Gastaut syndrome. Studies indicate a significant decrease in tonic and atonic seizure frequency as well as total seizure frequency compared to placebo-treated children. Rufinamide appears to be well tolerated and a safe medication, somnolence and vomiting being the most common side effects. Conclusions: Rufinamide is a promising adjunctive therapy for Lennox-Gastaut syndrome, an intractable childhood epilepsy. To ensure its optimal effectiveness, clinicians must be familiar with the medication's clinical response profile and potential for adverse effects.

Original languageEnglish (US)
Pages (from-to)547-551
Number of pages5
JournalNeuropsychiatric Disease and Treatment
Volume5
Issue number1
StatePublished - 2009
Externally publishedYes

Fingerprint

Anticonvulsants
Seizures
Brain Diseases
PubMed
Vomiting
Epilepsy
Therapeutics
Placebos
Lennox Gastaut Syndrome
rufinamide
Drug Resistant Epilepsy

Keywords

  • Epilepsy
  • Epileptic encephalopathy
  • Lennox-gastaut syndrome
  • Pediatric
  • Rufinamide

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry

Cite this

Update on the management of Lennox-Gastaut syndrome with a focus on rufinamide. / Stafstrom, Carl.

In: Neuropsychiatric Disease and Treatment, Vol. 5, No. 1, 2009, p. 547-551.

Research output: Contribution to journalArticle

@article{ccfca4697c0d4b269ab40d6007a158ee,
title = "Update on the management of Lennox-Gastaut syndrome with a focus on rufinamide",
abstract = "Objective: This review summarizes the treatment of Lennox-Gastaut syndrome, an intractable epileptic encephalopathy of early childhood. In particular, the review focuses on rufinamide, a recently released anticonvulsant medication with reported effectiveness in this epilepsy syndrome. Methods: A systematic literature search (PubMed) was performed to review the existing literature pertaining to the treatment of Lennox-Gastaut syndrome as well as studies involving rufinamide as an anticonvulsant medication. Results: The published literature to date documents a beneficial effect of rufinamide on children over 4 years old with Lennox-Gastaut syndrome. Studies indicate a significant decrease in tonic and atonic seizure frequency as well as total seizure frequency compared to placebo-treated children. Rufinamide appears to be well tolerated and a safe medication, somnolence and vomiting being the most common side effects. Conclusions: Rufinamide is a promising adjunctive therapy for Lennox-Gastaut syndrome, an intractable childhood epilepsy. To ensure its optimal effectiveness, clinicians must be familiar with the medication's clinical response profile and potential for adverse effects.",
keywords = "Epilepsy, Epileptic encephalopathy, Lennox-gastaut syndrome, Pediatric, Rufinamide",
author = "Carl Stafstrom",
year = "2009",
language = "English (US)",
volume = "5",
pages = "547--551",
journal = "Neuropsychiatric Disease and Treatment",
issn = "1176-6328",
publisher = "Dove Medical Press Ltd.",
number = "1",

}

TY - JOUR

T1 - Update on the management of Lennox-Gastaut syndrome with a focus on rufinamide

AU - Stafstrom, Carl

PY - 2009

Y1 - 2009

N2 - Objective: This review summarizes the treatment of Lennox-Gastaut syndrome, an intractable epileptic encephalopathy of early childhood. In particular, the review focuses on rufinamide, a recently released anticonvulsant medication with reported effectiveness in this epilepsy syndrome. Methods: A systematic literature search (PubMed) was performed to review the existing literature pertaining to the treatment of Lennox-Gastaut syndrome as well as studies involving rufinamide as an anticonvulsant medication. Results: The published literature to date documents a beneficial effect of rufinamide on children over 4 years old with Lennox-Gastaut syndrome. Studies indicate a significant decrease in tonic and atonic seizure frequency as well as total seizure frequency compared to placebo-treated children. Rufinamide appears to be well tolerated and a safe medication, somnolence and vomiting being the most common side effects. Conclusions: Rufinamide is a promising adjunctive therapy for Lennox-Gastaut syndrome, an intractable childhood epilepsy. To ensure its optimal effectiveness, clinicians must be familiar with the medication's clinical response profile and potential for adverse effects.

AB - Objective: This review summarizes the treatment of Lennox-Gastaut syndrome, an intractable epileptic encephalopathy of early childhood. In particular, the review focuses on rufinamide, a recently released anticonvulsant medication with reported effectiveness in this epilepsy syndrome. Methods: A systematic literature search (PubMed) was performed to review the existing literature pertaining to the treatment of Lennox-Gastaut syndrome as well as studies involving rufinamide as an anticonvulsant medication. Results: The published literature to date documents a beneficial effect of rufinamide on children over 4 years old with Lennox-Gastaut syndrome. Studies indicate a significant decrease in tonic and atonic seizure frequency as well as total seizure frequency compared to placebo-treated children. Rufinamide appears to be well tolerated and a safe medication, somnolence and vomiting being the most common side effects. Conclusions: Rufinamide is a promising adjunctive therapy for Lennox-Gastaut syndrome, an intractable childhood epilepsy. To ensure its optimal effectiveness, clinicians must be familiar with the medication's clinical response profile and potential for adverse effects.

KW - Epilepsy

KW - Epileptic encephalopathy

KW - Lennox-gastaut syndrome

KW - Pediatric

KW - Rufinamide

UR - http://www.scopus.com/inward/record.url?scp=70449721894&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70449721894&partnerID=8YFLogxK

M3 - Article

C2 - 19898669

AN - SCOPUS:70449721894

VL - 5

SP - 547

EP - 551

JO - Neuropsychiatric Disease and Treatment

JF - Neuropsychiatric Disease and Treatment

SN - 1176-6328

IS - 1

ER -